UPDATE: Sophiris Bio Separately Announces A Patient Death Occurred On Same Day As 2nd Administration Of The Topsalysin, Company Currently Investigation The Cause And Has Ceased Secondary Dosing Of Patients As A Precaution
Benzinga Newsdesk